Loading...

Implications for pharmaceutical companies and clinicians from the Bayer v NHS judgement: an increasing budgetary focus for both

The English High Court recently dismissed the Bayer pharmaceutical company’s challenge against a regional clinical commissioning group’s policy allowing NHS Trusts to use a cheaper, but unlicensed, alternative to a sight preserving eye treatment. This makes sober reading for companies marketing “on-...

Full description

Saved in:
Bibliographic Details
Published in:Eye (Lond)
Main Authors: Hyry, Hanna I., Roos, Jonathan C. P.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group UK 2018
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6461787/
https://ncbi.nlm.nih.gov/pubmed/30498264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41433-018-0280-3
Tags: Add Tag
No Tags, Be the first to tag this record!